Twenty years of hard work and a hundred years of road to start the journey again
Release time:
2020-08-14
二十年砥砺奋进 百年路再启征程
——浙江尖峰药业有限公司成立20周年回望
1998年12月31日,作为从水泥行业起家的上市公司尖峰集团跨行业发展的重要成果——浙江尖峰药业有限公司注册成立了。经过整整20年的艰苦创业和拼搏发展,截止目前,尖峰药业总资产达到14.93亿元,拥有下属全资、控股和参股药品生产企业7家、药品经营企业3家、国家级博士后科研工作站4家、省级院士专家工作站2家,拥有国际、国内药品发明专利52项,主导产品市场占有率排名前3。公司先后多次获评全国医药百强企业、浙江省医药工业十强企业、国家重点高新技术企业、国家知识产权示范企业,浙江省创新型示范企业、浙江省专利示范企业、浙江省“‘守合同,重信用’AAA企业”等系列荣誉,“尖峰”商标被认定为中国驰名商标。尖峰药业已经成为浙江省乃至全国有一定规模和影响力的综合性医药企业。
科技创新结硕果
新药开发是医药企业的龙头与生命。秉承“科技造就健康”的理念,从成立开始,尖峰药业便极为重视新药的开发工作,投入巨资与国内各大科研院所紧密合作,取得系列成果。
2000年3月,尖峰药业开发研制的第一只新药克拉霉素胶囊顺利获得生产批文,6月正式生产投放市场。
2000年12月,尖峰药业和中国药科大学联合研制开发的我国第一个沙星类国家一类新药加替沙星,获国家临床公告保护,保护期为12年,同时被列为省、市重大科技攻关项目。2003年1月,加替沙星正式投放市场,并被列入国家高技术产业化示范工程项目;2004年被授予“国家重点新产品”称号;2006年获得浙江省科技进步一等奖。
2002年8月,尖峰药业开发的国家级新药愈风宁心滴丸获准国内首家上市,填补了浙江省这一剂型的空白。
2002年10月,尖峰药业开发的心血管类抗高血压一线药物力斯得(门冬氨酸氨氯地平片)正式上市。
2004年5月,尖峰药业研制开发的第三代抗抑郁药舒坦罗(帕罗西汀)正式上市。
2004年8月,尖峰药业注射用盐酸头孢甲肟、甘油果糖注射液两个新药成功取得生产批文。10月,第三代半合成的头孢菌素类广谱抗生素——注射用盐酸头孢甲肟在国内首仿上市,长期占据了国内同类产品50%以上的市场份额。
2007年9月4日,尖峰药业研制开发的国内首家产品国家二类新药带状疱疹特效药——注射用喷昔洛韦获得国家药监局批准生产,并于2008年1月全球首家上市销售。
2009年2月,尖峰药业研制开发的又一国家级新药醋氯芬酸缓释片取得新药证书和生产批文,为国内独家剂型。
2017年3月,尖峰药业主持研发的国家一类新药注射用去氧鬼臼毒素取得临床试验批件,目前正由中国医学科学院肿瘤医院牵头,在全国各大医院开展临床试验。
……
在开发了众多新药、取得诸多科技创新成果的同时,尖峰药业公司和个人也取得了一系列荣誉。
尖峰药业于2002年8月被认定为金华市高新技术企业;2003年6月被认定浙江省高新技术企业;2007年10月通过国家火炬计划重点高新技术企业复审,成为国家级重点高新技术企业,此后连续四次通过高新技术企业认定;2011年9月获“浙江省创新型示范企业”称号、入围“中国医药工业企业百强”。集团董事长兼药业公司董事长蒋晓萌在2005年荣获国务院特殊津贴,2013年荣获“浙江省有突出贡献中青年专家”称号。集团副总经理、药业公司总经理黄金龙在2011年获 “浙江省优秀科技工作者”荣誉称号,2015年获“全国优秀科技工作者”荣誉称号。
在进行新药开发与科技创新的过程中,尖峰药业与相关高校、医药科研单位展开了广泛合作,成立了省级新药研究开发中心,与上海医药工业研究院、中国药科大学、四川抗菌素工业研究所、浙江工业大学、金华职业技术学院等单位建立了良好的合作关系,进行产学研的全面合作,并取得了双赢共利的可喜成果。
产能扩充壮实力
尖峰药业成立之初,是通过兼并收购临海制药厂、浙江金华生物化学制药厂,合资组建浙江迪耳江南分厂等进行药品生产的。在自主开发新药取得成果的同时,自建、扩建生产基地,增加企业产能和规模便提上日程。
2001年7月13日,尖峰药业秋滨制药基地项目破土动工,于2002年12月13日通过国家GMP认证,是当时华东地区最大的单体药厂。
2001年12月21日,尖峰药业江南制药厂综合制剂大楼扩建的三个车间、五种剂型通过国家GMP认证。
此后十多年的时间里,两个制药厂又历经了多次改、扩、建,仍不能满足尖峰药业日益增长的与销售相匹配的产能需求,新建一个全新的、更大规模的制造基地便提上了议事日程。
2012年7月31日,尖峰药业金西生产基地项目破土动工。经过近三年的建设,2015年6月,原江南厂全部搬迁完毕。6月15日,金西厂综合制剂车间开始投料生产。7月8日,首批产品醋氯芬酸缓释片离厂发货。从此,尖峰药业有了在浙江省乃至全国领先的、拥有一流制造设备和环境的、全新的大规模药品生产制造基地。
2018年8月3日,集团公司董事会又批准尖峰药业金西基地年产20亿片固体制剂项目投资计划,将面向欧盟和美国等国际市场出口药品,走向国际化发展道路。
随着尖峰药业制造规模和产能的扩大,很快确立了在医药行业的地位,早在2000年就被评为“浙江省十佳工业企业”和“浙江省医药工业十强企业”;2003年又名列“全国医药百强企业”;2008年名列全国医药企业总产值第34位;2010年和2011年,两度入选“中国医药工业百强企业”;2013年入选“中国医药行业十大最具成长力企业”……一个成熟的、高素质的现代医药企业迅速展现在世人面前,并在中国医药行业拥有了较高的知名度和影响力。
多元销售展新貌
产品营销关乎企业的生存。尖峰药业从成立开始,就有计划、有步骤地不断进行营销模式的整合,实现资源的优化配置,充分发挥各个企业的优势,从而扬长避短,协调发展,齐头并进。
从1998年注册成立,尖峰药业便下大力气组建自身工业产品的销售队伍,在全国各省市建立办事处,大力拓展药品代理和终端业务市场,销售规模、总额、利润不断上升。除此之外,像盐酸头孢甲肟、盐酸胺碘酮、吗替麦考等产品则采用了全国业务总代理的销售模式,也取得了相当不错的销售业绩。
1999年,金华市医药商业系统进行了有史以来最大的一次资产重组,尖峰药业公司联合尖峰集团以2208万元一次性买断金华市医药公司的全部资产。曾经是金华地区唯一的医药批发企业的金华市医药公司,从此成为尖峰药业的下属企业,专门从事医药商业批发业务。兼并整合之后,金华市医药公司以其全流通、高周转的业务模式,为尖峰药业迅速扩大整体销售规模、提升销售总额做出了重要贡献。
2001年,尖峰药业在原金华市医药公司下属零售药店的基础上注册成立尖峰大药房连锁有限公司,建立起以金华市区为中心,辐射周边县、市、乡镇的药品零售网络。自成立以来,尖峰大药房以其高质量、周到服务的零售模式迅速发展成为金华药品零售的领头企业之一,随着国家处方权的放开,将进一步发展壮大。这对扩大尖峰品牌影响、社会知名度起到了重要作用。
在多种销售齐头并进的良好格局之下,尖峰药业的销售规模迅速扩大。2008年名列中国化学制药工业协会医药工业企业产品销售收入排名第31位和利润总额排名第54位。2010年荣获由《医药观察家报》评选的“最具成就企业奖”。2016年和2018年两度荣获“最具品牌价值奖”。
联合兼并拓规模
尖峰药业从成立之初,便打破地域的限制,对外进行投资,借助外地的技术和人才资源,迅速扩大公司规模,提升公司技术水平。
1999年,尖峰药业在天津投资100万元组建成立高新技术企业——天津市尖峰天然产物研究开发公司,专业从事植物提取物的技术研究和产品开发,多项产品出口国际市场,现已成为国内植物提取物行业的领军企业,提取物联盟的理事长单位,主持制定了多项植物提取的技术标准,取得了良好的经济效益和社会效益。后来在天津又投资了天津尖峰弗兰德医药技术公司。
2016年,尖峰药业控股成立中德合资浙江金得尔儿婴药品有限公司(尔婴公司),以此为基础,引进德国技术和产品,进军婴幼儿药品市场。
2017年,尖峰药业与相关各方签订《关于北京慧宝源生物技术股份有限公司之增资和股份转让协议》,分四期投资,以北京慧宝源生物技术股份有限公司及其控股子公司广西慧宝源生物技术有限公司为平台,共同合作开展新药研发、药品生产经营等医药业务合作。
2018年1月,尖峰药业与相关各方签订了系列协议,通过收购股份和增效的方式对上海北卡医药技术有限公司进行投资,以上海北卡及其子公司为平台,建立原料药和中间体的研发、生产基地,进一步延伸并完善产业链,增加产业规模,提高研发能力,为尖峰药业原料药生产提供可靠保障。8月,集团公司董事会批准尖峰药业公司对上海北卡医药公司进行增资、尖峰药业下属上海北卡医药公司收购安徽众望制药公司两项投资计划,尖峰药业版图再次扩张。
通过近二十年的对外投资、兼并、整合,尖峰药业建立了一条从上游原料药到下游制剂产品的完整产业链,并借助外地大城市企业的技术和人才优势,建立了一个巨大的合作共赢的平台,为尖峰药业在深耕国内市场多年的基础上进军国际市场作好准备,为未来的长远发展打下了良好的基础。
知识产权管理显特色
作为从事医药产品制造与销售的企业,具有相对较高的技术含量,尖峰药业从一开始便注重对知识产权的保护与管理,积极参与商标、专利的申报。
2008年,尖峰药业“利欧”“立肖均”两只商标被认定为金华市著名商标。2012年,“尖峰”商标成为浙江省著名商标,2016年成为“中国驰名商标”。目前,尖峰药业拥有国内、国际药品发明专利52项,2013年被认定为浙江省专利示范企业。
2015年,尖峰药业专门召开《企业知识产权管理规范》贯标启动大会,全面加强知识产权管理工作。2016年,尖峰药业通过知识产权管理体系认证;2017年4月被评为国家知识产权优势企业,得分名列金华参评企业榜首;同年12月,又被确定为国家知识产权示范企业,为金华市本级企业首家,填补金华市本级空白。
通过这一系列的知识产权管理活动,取得了优异的成果,扩大了公司的品牌影响力和社会美誉度。
热心公益担责任
作为上市公司尖峰集团的子公司,尖峰药业一直热心社会公益事业,在全力做好公司自身的质量、安全、环保本职工作之外,多次参与公益行动并进行捐赠,切实承担起了企业的社会责任。
1999年,尖峰药业捐赠3万元支援西藏那曲地区医药事业;2002年,捐赠28台近百万的制药设备给新疆墨玉县以支援当地经济建设;2003年,捐赠价值28<
More information
Recently, it was learned from the competent department that the "ERP/MES full-process informatization" project of Jianfeng Pharmaceutical Company has been included in the list of key projects of "integration of industrialization and industrialization" in Jinhua City, and has now entered the publicity period. In order to speed up the in-depth integration of informatization and industrialization, according to the evaluation criteria in Jinhua City's "Several Opinions on Accelerating Informatization Construction" and "Jinhua City Informatization and Industrialization Integration Key Project Management Measures", 148 projects were included in 2017 Jinhua City's "Integration of Industrialization and Industrialization" key projects. The "ERP/MES Full Process Informatization" project of Jianfeng Pharmaceutical Co., Ltd. was finally included in the list after being recommended, material reviewed and expert reviewed by Jinhua Economic and Information Committee. The ERP-level subsystems of ERP/MES full-process informatization project include sales system, procurement system, MRP system, GMPQbD system, connecting UFIDA financial software and HR system. MES-level subsystems include industrial data acquisition and monitoring system, GAMP/MES system, eBPR (electronic batch production record system), cGMP quality assurance system, QC/eBTR(QC process and electronic batch inspection record system), LIMS system, etc. After the construction is completed, the visualization of drug production process and the collection and integration of industrial data will be realized. Realize the electronization of drug production process parameters, electronic batch production and inspection records; the realization of big data integration of industrial data and information will also be in line with the regulatory concept of GMP data integrity and quality traceability to the greatest extent. The establishment of a unified enterprise information platform will eliminate information islands and realize data one.
2020
07-31
The company's first-half profit record high
According to the 15th meeting of the ninth board of directors of the company on August 25, in the first half of 2017, the company achieved a net profit of 240.5357 million yuan, the highest level in half a year's history. In the first half of 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening management, and improving efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, strengthening lean production and management improvement internally, and actively exploring externally Develop new opportunities and continue to promote the "three reductions and three improvements" work. Through the joint efforts of all employees of the company, the best semi-annual performance in history has been achieved. As of the end of June 2017, the company's total assets were 4.226 billion yuan and net assets were 2.511 billion yuan; the company achieved total operating income of 1,305.9327 million yuan, an increase of 18.42 percent over the same period last year, and net profit attributable to owners of the parent company was 240.5357 million yuan, an increase of 132.11 percent over the same period last year. Earnings per share are 0.7 yuan. In the second half of the year, the company will continue to focus on the annual business plan, carry out in-depth work of "three reductions and three improvements", further do a good job in internal control, prevent business risks, and further do a good job in safety and environmental protection. we will further develop and improve the complementary relatively diversified main business structure and constantly enhance the company's core competitiveness. The 15th meeting of the 9th board of directors held on August 25 was presided over by Jiang Xiaomeng, chairman of the group company. Four proposals and reports including the 2017 semi annual report and the proposal on the change of the company's accounting policy were deliberated and passed. on the same day, the 12th meeting of the eighth board of supervisors was held,
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-30
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31
Spike Pharmaceuticals set out to explore a new sales model
Agency and Terminal Link Production and Chain Cooperation Spike Pharmaceuticals to Explore New Sales Models From August 16 to 21, the 2017 China Pharmaceutical Retail Industry Information Conference (hereinafter referred to as "Xipu Conference") with the theme of "Building a Blueprint-Market Awakening Focusing on Demand" was held in Boao, Hainan. Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and relevant leaders of Spike Health, pharmaceutical sales company and Spike Pharma pharmacy were invited to attend the event, to create a new sales model "road". This year coincides with the 10th anniversary of the Western Conference. More than 1200 mainstream chain pharmacies, more than 800 brand pharmaceutical industries, more than 100 cross-border affiliated institutions, more than 130 top domestic and foreign capital institutions, more than 60 representatives of authoritative media, and authoritative experts in the industry, with nearly 4000 people gathered in Boao. The meeting combed the context of the pharmaceutical retail industry in the past ten years, discussed the development of the industry in the new decade, and built a new blueprint for the industry. During the meeting, Huang Jinlong led the peak participants to have in-depth exchanges with the organizers of the conference and industry experts on issues such as the impact of national policies such as the brand strategy of enterprises, the role of brand enterprises in the industry, medical reform, prescription outflow, etc. on the original sales mode of pharmaceutical enterprises. He also had extensive contact with pharmaceutical counterparts and terminal chains, listened to front-line sales experience, collected relevant information on terminal chains, and collected market trends of the top 100 chains. In the past ten years, the scale of drug retail sales in China has increased from 143 billion yuan to 337.7 billion yuan, and the chain rate has increased from 35.3 percent to 49.4 percent.
2020
07-31
General Manager Yu Jianhong to Yunnan Peak to Guide Work
On August 23, Yu Jianhong, general manager of the group company, went to Yunnan Jianfeng cement company for investigation and guidance, and put forward requirements for the key work in the last few months of this year. At the peak of Yunnan Province, Yu Jianhong went deep into the production site to learn more about the current production and operation situation, and convened the middle-level and above management backbones to have in-depth exchanges and discussions with everyone on the problems existing in work efficiency changes, personnel stability, current production and management after the implementation of post optimization and re-organization. Since the beginning of this year, Yunnan's peak production and sales volume, profits and various technological and technical indicators have been relatively ideal. The kiln output in April has also reached the best level since it was put into production. The development and maintenance of the market, the environmental management of the factory area, and the professional quality and mental state of cadres and workers have also been greatly improved. While fully affirming the above achievements, Yu Jianhong pointed out that as the homogenization of the cement market becomes more and more serious, the market changes faster and faster. If we can't recognize the situation and seize the opportunity, enterprises will face more and more problems. In this case, the management backbone should give full play to the role of the backbone, quickly change the management concept, and strive to improve the competitiveness of enterprises. In view of the focus of work in the last four months of this year, Yu Jianhong put forward the following requirements for Yunnan Jianfeng: break the inherent concept of post functions and responsibilities, set up posts and organizational structures around logistics, people flow and capital flow, and cultivate and forge a team that can fight well. To further implement the training of job skills and quality, managers should take the lead in strengthening their own learning and formulate annual, monthly and weekly training plans, through the combination of internal and external training, theory and practice.
2020
07-31